Neoplasm Treatment Market Size & Share, by Type (Malignant, Benign); End-user (Specialty Clinics, Hospital, Cancer Research Center) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

  • Report ID: 3898
  • Published Date: Mar 01, 2023
  • Report Format: PDF, PPT

Companies Dominating the Neoplasm Treatment Landscape

    • Thermo Fisher Scientific Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Bayer AG
    • Merck & Co., Inc.
    • Novartis AG
    • Abbott Laboratories
    • Exelixis, Inc.
    • Boehringer Ingelheim GmbH
    • Teva Pharmaceutical Industries Ltd.
    • F. Hoffmann-La Roche
    • Amgen Inc.

Browse Key Market Insights with Data Illustration:


In The News

  • Exelixis Inc. announced the successful results for Cabozantinib in combination with immunotherapies in patients with advanced colorectal cancer.

  • Merck & Co announced the complete acquisition of Acceleron Pharma Inc., to explore the opportunities in medical research.

Author Credits:  Radhika Gupta, Shivam Bhutani

  • Report ID: 3898
  • Published Date: Mar 01, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Surging change in genetic mutations, increasing geriatric population are the major factors driving the market growth.

The market is anticipated to attain a CAGR of 10% over the forecast period, i.e., 2023-2035.

Lack of awareness among people in low and middle-income countries for these treatment, and lack of medical reimbursement policies for treatment of neoplasm are estimated to be the growth hindering factors for the market expansion.

The market in the North America region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.

The major players in the market are Thermo Fisher Scientific Inc., Bayer AG, Merck & Co., Inc., Novartis AG, Abbott Laboratories, Exelixis, Inc., Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche, Amgen Inc., and others

The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by type, end user, and by region.

The malignant segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
Inquiry Before Buying Request Free Sample

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying